BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24667985)

  • 21. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
    Khanna A; Pimanda JE; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
    Hung MH; Wang CY; Chen YL; Chu PY; Hsiao YJ; Tai WT; Chao TT; Yu HC; Shiau CW; Chen KF
    Oncotarget; 2016 Jan; 7(1):638-55. PubMed ID: 26575017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CIP2A inhibits PP2A in human malignancies.
    Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
    Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion.
    Li J; Yang XF; Ren XH; Meng XJ; Huang HY; Zhao QH; Yuan JH; Hong WX; Xia B; Huang XF; Zhou L; Liu JJ; Zou F
    Biochem Biophys Res Commun; 2014 Oct; 453(1):7-12. PubMed ID: 25234598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
    Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
    Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
    Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
    Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein Phosphatase 2a Inhibits Gastric Cancer Cell Glycolysis by Reducing MYC Signaling.
    Cai Z; Zhang W; Zhou R; Wang Y; Feng Y
    Cell Biochem Biophys; 2023 Mar; 81(1):59-68. PubMed ID: 36324030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SETting OP449 into the PP2A-activating drug family.
    Neviani P; Perrotti D
    Clin Cancer Res; 2014 Apr; 20(8):2026-8. PubMed ID: 24634375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradation of β-catenin.
    Wu MY; Xie X; Xu ZK; Xie L; Chen Z; Shou LM; Gong FR; Xie YF; Li W; Tao M
    Oncol Rep; 2014 Aug; 32(2):513-22. PubMed ID: 24926961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling.
    Hein AL; Seshacharyulu P; Rachagani S; Sheinin YM; Ouellette MM; Ponnusamy MP; Mumby MC; Batra SK; Yan Y
    Cancer Res; 2016 Apr; 76(8):2243-2253. PubMed ID: 26893480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.
    Chien W; Sun QY; Lee KL; Ding LW; Wuensche P; Torres-Fernandez LA; Tan SZ; Tokatly I; Zaiden N; Poellinger L; Mori S; Yang H; Tyner JW; Koeffler HP
    Mol Oncol; 2015 Apr; 9(4):889-905. PubMed ID: 25637283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
    Fujiwara N; Kawasaki H; Yabe R; Christensen DJ; Vitek MP; Mizuno T; Sato K; Ohama T
    J Vet Med Sci; 2013; 75(3):349-54. PubMed ID: 23131782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceramide in the prostate.
    Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.
    Christensen DJ; Ohkubo N; Oddo J; Van Kanegan MJ; Neil J; Li F; Colton CA; Vitek MP
    J Immunol; 2011 Feb; 186(4):2535-42. PubMed ID: 21289314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
    Li W; Chen Z; Gong FR; Zong Y; Chen K; Li DM; Yin H; Duan WM; Miao Y; Tao M; Han X; Xu ZK
    Eur J Cancer; 2011 Nov; 47(17):2654-64. PubMed ID: 21958460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
    Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
    Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
    Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
    FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
    Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
    Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-expression of FOXL1 and PP2A inhibits proliferation inducing apoptosis in pancreatic cancer cells via promoting TRAIL and reducing phosphorylated MYC.
    Li Y; Yu D; Sheng W; Song H; Li Y; Dong M
    Oncol Rep; 2016 Apr; 35(4):2198-206. PubMed ID: 26820810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.